Safety of Four COVID-19 Vaccines across Primary Doses 1, 2, 3 and Booster: A Prospective Cohort Study of Australian Community Pharmacy Vaccinations

Safety of Four COVID-19 Vaccines across Primary Doses 1, 2, 3 and Booster: A Prospective Cohort Study of Australian Community Pharmacy Vaccinations

Four COVID-19 vaccines are approved for use in Australia: Pfizer-BioNTech BNT162b2 (Comirnaty), AstraZeneca ChAdOx1 (Vaxzevria), Moderna mRNA-1273 (Spikevax) and Novavax NVX-CoV2373 (Nuvaxovid). We sought to examine adverse events following immunisation (AEFI) at days 3 and 42 after primary doses 1,...

Full description

Bibliographic Details
Main Authors: Sandra M. Salter, Dani Li, Kevin Trentino, Lisa Nissen, Kenneth Lee, Karin Orlemann, Ian Peters, Kevin Murray, Alan Leeb, Lucy Deng
Format: Article
Language:English
Published: MDPI AG 2022-11-01
Series:Vaccines
Subjects:
COVID-19
pharmacy
vaccine
safety
adverse events
surveillance
Online Access:https://www.mdpi.com/2076-393X/10/12/2017

Internet

https://www.mdpi.com/2076-393X/10/12/2017

Similar Items